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Upon activation by the ligands Gas6 and Protein S,
Tyro3/Axl/Mer (TAM) receptor tyrosine kinases pro-
mote phagocytic clearance of apoptotic cells and
downregulate immune responses initiated by Toll-
like receptors and type I interferons (IFNs). Many
enveloped viruses display the phospholipid phos-
phatidylserine on their membranes, through which
they bindGas6 andProtein S and engageTAM recep-
tors. We find that ligand-coated viruses activate TAM
receptors on dendritic cells (DCs), dampen type I IFN
signaling, and thereby evade host immunity and pro-
mote infection. Upon virus challenge, TAM-deficient
DCs display type I IFN responses that are elevated
in comparison to wild-type cells. As a consequence,
TAM-deficient DCs are relatively resistant to infection
by flaviviruses and pseudotyped retroviruses, but
infection can be restored with neutralizing type I IFN
antibodies. Correspondingly, a TAM kinase inhibitor
antagonizes the infection of wild-type DCs. Thus,
TAM receptors are engaged by viruses in order to
attenuate type I IFN signaling and represent potential
therapeutic targets.
INTRODUCTION
Virus infection of vertebrate cells elicits innate immune
responses that are triggered by type I interferons (IFNs) and
proinflammatory cytokines (Zuniga et al., 2007). These immune
responses are initially induced by the recognition of virus nucleic
acids by host pattern recognition receptors, which include Toll-
like receptors (TLRs), RIG-I-like receptors, and cytosolic DNA
sensors (Thompson et al., 2011). After virus engagement, these
sensors activate signal transduction pathways that induce type I
IFNs (multiple IFNa and IFNb), which, in turn, stimulate the
production of antiviral cellular restriction factors in order to
control virus replication (Yan and Chen, 2012). Consequently,136 Cell Host & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevipathogenic viruses have evolved specific countermeasures for
evading or interfering with these protective host responses
(Yan and Chen, 2012).
The Tyro3/Axl/Mer (TAM) receptor tyrosine kinases (RTKs)
Tyro3, Axl, and Mer (Lai and Lemke, 1991; Lemke, 2013; Lemke
and Rothlin, 2008) and their cognate ligands Protein S and Gas6
(Stitt et al., 1995) are negative regulators of the innate immune
response to microbial infection. They are activated at the end
of this response (Rothlin et al., 2007) and exert their immunosup-
pressive functions through two interlinked mechanisms. First,
they promote the rapid phagocytic clearance of apoptotic cells
(ACs) by macrophages, dendritic cells (DCs), and other dedi-
cated phagocytes (Lemke and Burstyn-Cohen, 2010; Lemke
and Rothlin, 2008). Both Protein S and Gas6 have a g-carboxyl-
ated ‘‘Gla domain’’ at their amino termini that allows them to bind
to phosphatidylserine (PtdSer), which is displayed on the surface
of ACs. This phospholipid is among the most common and
potent of the ‘‘eat me’’ signals throughwhich ACs are recognized
by phagocytes (Ravichandran, 2011), given that PtdSer is nor-
mally confined to the inner leaflet of the plasma membrane
bilayer in healthy cells. Then, through their carboxy termini, Pro-
tein S and Gas6 bind and activate TAM receptors that are ex-
pressed on the surface of phagocytes, thereby ‘‘bridging’’ the
phagocyte to the AC that it will engulf. In a second, mechanisti-
cally-linked action, the binding of Gas6 or Protein S to TAM re-
ceptors on macrophages or DCs activates a negative feedback
loop that inhibits innate immune responses initiated by TLR and
type I IFN signaling pathways (Lemke and Lu, 2003; Lemke and
Rothlin, 2008; Lu and Lemke, 2001; Rothlin et al., 2007). In
DCs, this negative feedback is achieved through Axl-mediated
induction of the genes encoding the suppressor of cytokine
signaling (SOCS) proteins 1 and 3 (Rothlin et al., 2007: Yoshi-
mura et al., 2012).
Several gain-of-function studies have implicated TAM recep-
tor-ligand interactions in promoting infection by enveloped
viruses. Ectopic expression of one or more TAM receptors into
infection-resistant cell lines (e.g., human embryonic kidney
[HEK] 293T cells) has been found to potentiate infection by
both filoviruses (e.g., Ebola virus) and HIV-derived model lentivi-
ruses (Brindley et al., 2011; Hunt et al., 2011; Morizono et al.,
2011; Shimojima et al., 2007; Shimojima et al., 2012; Shimojimaer Inc.
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potentiation of infection by Dengue (DENV) and West Nile
(WNV) viruses (Meertens et al., 2012)—two flaviviruses that are
global health concerns (Bhatt et al., 2013; Suthar et al., 2013).
TAM receptor facilitation of viral infection has been interpreted
generally in the context of the TAM ligand bridging activity
outlined above for ACs, given that many enveloped viruses—
including WNV, DENV, HIV-1, Ebola, Marburg, Amapari, Tacar-
ibe, Chikungunya, and Eastern Equine Encephalitis viruses,
among others—also display PtdSer on the external leaflet of their
membrane envelopes (Jemielity et al., 2013; Mercer, 2011). For
example, PtdSer on the surface of DENV virions can be detected
by PtdSer-specific antibodies and by the PtdSer-binding protein
annexin V, and preincubation with annexin V diminishes DENV
infectivity (Meertens et al., 2012). Similarly, PtdSer on the
HIV-1 envelope is a cofactor for the infection of monocytes,
and HIV-1 can be purified with annexin V (Callahan et al., 2003).
These observations have led to the hypothesis that viruses
attach and gain access to cells via the imitation of ACs in
a PtdSer-dependent process termed ‘‘apoptotic mimicry’’
(Jemielity et al., 2013; Mercer and Helenius, 2008, 2010). For
the TAM system, this mimicry does not involve a direct interac-
tion of TAM receptor with virus but rather an interaction between
TAM receptor and virions that are opsonized with a TAM ligand
(Meertens et al., 2012; Mercer, 2011). For this mechanism to
operate, enveloped viruses must be exposed to an environment
that contains Protein S or Gas6, and the target cell must express
one or more TAM receptors. Given that Protein S is present at
300 nM in the vertebrate bloodstream (Burstyn-Cohen et al.,
2009; Garcı´a de Frutos et al., 2007), it is likely that many
blood-borne enveloped viruses carry this TAM ligand in vivo.
The action of the TAM system during enveloped virus infection
has been thought to be restricted to the facilitation of virus
attachment and entry into the target cell (Brindley et al., 2011;
Frei et al., 2012; Hunt et al., 2011; Meertens et al., 2012;
Morizono et al., 2011; Shimojima et al., 2007; Shimojima et al.,
2012; Shimojima et al., 2006) (Figure 1A). However, we reasoned
that ligand-coated virions should also act as potent TAM
agonists because of the multimerization, concentration, and
immobilization of Gas6 or Protein S on the virion surface and
that activation of TAM receptors by ligand-coated viruses
should, in turn, inhibit the type I IFN response in target cells
(Rothlin et al., 2007). Accordingly, we hypothesized that cells
deficient in TAM receptor expression or signaling should be
relatively resistant to virus infection. In this report, we test these
predictions. We show that TAM-deficient DCs are less suscepti-
ble to infection by retroviruses and flaviviruses, that reduced
infectivity is due to elevated type I IFN production, and that a
small-molecule TAM kinase inhibitor attenuates virus infection
of wild-type (WT) DCs. These results identify a general immune
evasion mechanism by which enveloped viruses engage TAM
receptors in order to inhibit type I IFN signaling.
RESULTS
Ectopic Expression of TAM Receptors Enhances Virus
Infection
First, we employed a gain-of-function approach similar to those
used previously (Brindley et al., 2011; Hunt et al., 2011; MeertensCell Hoset al., 2012; Morizono et al., 2011; Shimojima et al., 2007; Shimo-
jima et al., 2012; Shimojima et al., 2006). Tyro3, Axl, or Mer were
each expressed stably in HEK 293T cells, which are not readily
infected by HIV-1-derived retroviruses. Using a western blot,
we confirmed that the three TAM receptors were each highly
expressed in the stably transfected HEK 293T cell lines (Fig-
ure 1B). These blots also demonstrated that parental HEK
293T cells express low and moderate levels of endogenous
Mer and Tyro3, respectively, but do not express Axl (Figure 1B).
The clonal HEK 293T cell lines were exposed to a single-cycle,
replication-incompetent, HIV-1-derived virus vector that was
pseudotyped with one of four different viral glycoproteins
(GPs)—Ebola virus GP, Marburg virus GP, vesicular stomatitis
virus GP (VSVg), or amphotropic murine leukemia virus Env—
as model enveloped viruses. Infection experiments were con-
ducted with cell culture medium supplemented with 10% fetal
bovine serum (FBS), which contained 30 nM of the TAM ligand
Protein S. (As detailed below, we confirmed that these HIV-1-
derived viruses bind Protein S in a Ca+2-dependent manner.)
Virus infection was monitored by measuring reverse transcribed
HIV-1 DNA produced at 24 hr postinfection (Ko¨nig et al., 2008)
(Figure 1C).
Cells ectopically expressing individual TAM receptors were 2-
to 10-fold more susceptible to infection by all four pseudotyped
viruses than WT HEK 293T cells. Because the viruses used have
different particle:infectivity ratios, we conclude that receptor-
specific effects on virus infection are largely independent of viral
glycoprotein type (Figure 1C). We attempted to determine
whether one of more of the TAM receptors were activated (tyro-
sine phosphorylated) during virus challenge—an assessment
that has not yet been made for any viral infection. However, we
found that the high-level expression of one receptor (e.g., Axl
in 293Axl cells) led to the constitutive activation of all TAM recep-
tors in the same HEK 293T cell, even in the absence of virus
(Figure 1D). These data highlight the difficulties associated with
using gain-of-function approaches to assign specific functions
to individual TAM receptors during virus infection.
TAM Receptors Are Required for Efficient Lentiviral
Infection of Dendritic Cells
Therefore, we conducted loss-of-function studies with bone-
marrow-derived DCs (BMDCs) prepared from WT or specific
TAM gene knockout mice (Lu et al., 1999). WT BMDCs express
both Axl andMer but only express very low levels of Tyro3 (Roth-
lin et al., 2007). We found that infection by all four pseudotyped
viruses was dependent upon BMDC expression of TAM recep-
tors (Figure 1E). As for the HEK 293T cell gain-of-function exper-
iments, these BMDC loss-of-function studies were conducted
with serum-supplemented (e.g., Protein S-containing) culture
medium. Protein S is a ligand for Mer and Tyro3, but it does
not activate Axl (Lemke and Rothlin, 2008; Prasad et al., 2006;
Stitt et al., 1995). Serum does not contain appreciable levels of
Gas6, the pan-TAM ligand (Lemke and Rothlin, 2008; Stitt
et al., 1995; Ekman et al., 2010), and BMDCs did not secrete
detectable levels of this protein.
Consistent with Mer expression in BMDCs and this receptor’s
ligand specificity, virus infection of BMDCs was strongly depen-
dent on Mer: the low levels of infection seen with TAM triple
knockout (TKO) animals were recapitulated with cells derivedt & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevier Inc. 137
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Figure 1. Gain- and Loss-of-Function Studies for Evaluating the Impact of TAM Receptors on Virus Infection
(A) Existing model of TAM receptor-ligand facilitation of enveloped virus entry. PtdSer, phosphatidylserine.
(B) Immunoblots showing expression of individual TAM receptors in HEK 293T cells either untransfected (293) or stably transfectedwith individual TAM receptors.
(C) Levels of HIV-1 viral DNA produced 24 hr postinfection of the indicated HEK 293T transformants (from B) by pseudotyped viruses bearing envelope
glycoproteins from VSVg, Ebola, Marburg, or MLV-A viruses. Levels shown were normalized to those obtained with untransfected HEK 293T cells for each
pseudotype (defined as 100%, dashed blue line).
(D) Immunoblots showing constitutive activation of all three types of TAM receptor in HEK 293T cells that ectopically express Axl. First, TAM receptors were
immunoprecipitated with the indicated antibodies and subjected to SDS-PAGE before being immunobloted with receptor-specific antibodies (IB: Tyro3, Axl, or
Mer) or with a phosphotyrosine-specific antibody (IB: pY).
(E) BMDCs generated from WT or specific TAM receptor knockout mice were infected with HIV-1-derived virus pseudotyped with the indicated viral glyco-
proteins, and the levels of reverse transcribed HIV-1 DNAweremeasured at 24 hr postinfection. Levels shownwere normalized to those seen withWT BMDCs for
each pseudotype (100%, dashed blue line). A, Axl; M, Mer; T, Tyro3; KO, single knockout; DKO, double knockout; TKO triple TAM receptor knockout. *p < 0.05;
**p < 0.01; ***p < 0.001. Error bars are SEM of samples from three independent experiments. VSVg, EbGP, MARVGP, and MLV-A denote the glycoproteins of
vesicular stomatitis, Ebola, Marburg, and amphotropic murine leukemia virus, respectively. See also Figure S1.
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Figure 2. TAM Activity Stimulates Postentry Events during Virus Infection
(A) BMDCs prepared from wild-type (WT, blue) or Axl/Mer/ (AM DKO, red) mice were infected with VSVg-pseudotyped HIV-1-derived viruses carrying a
Vpr-BLAM fusion protein (see the Experimental Procedures) and maintained at either 4C or 37C, as indicated, for 4 hr. Then, cells were loaded with the
fluorescent b-lactamase (BLAM) substrate CCF2, and BLAM activity was assayed. Error bars are SD of six samples. Results are representative of three
independent experiments.
(B) Axl-transfected (293 Axl) and kinase-dead Axl-transfected (293 AxlKD) HEK 293T cells were treatedwith (+) or without () 10 nM recombinant mouseGas6, and
lysates from these cells were immunoprecipitated with anti-HA. (The cDNA expression constructs for both Axl proteins were HA-tagged.) Protein equivalents of
the IPs were immunoblotted with anti-pY (top blot) or anti-HA (bottom blot).
(C) Wild-type (293 WT, panels 1–3), Axl-transfected (293 Axl, panel 4), and kinase-dead Axl-transfected (293 AxlKD, panel 5) stable HEK 293T cell lines were
infected with WNV at moi = 10, and the presence of internalized WNV was scored by confocal immunofluorescence microscopy for WNV E protein (E16, red,
panels 1 and 3–5) at 4 hr postinfection. Panel 2 is a control staining with a monoclonal antibody (CHKV-152) against chikungunya virus. Nuclei of HEK 293T cells
are visualized with DAPI (blue). One representative of three independent experiments is shown.
(D) Axl-transfected (Axl, blue) and kinase-dead Axl-transfected (293 AxlKD, red) stable HEK 293T cell lines were infected with WNV at moi = 0.01 and scored for
virus replication as plaque-forming units (PFU; see the Experimental Procedures) at 4 and 24 hr postinfection. Error bars are SD of three samples. Results are
representative of three independent experiments.
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DKO) mice (Figure 1E). In comparison to Mer and Tyro3 KO, loss
of Axl, which, in other cell types, has been found to be a cofactor
for virus entry (Brindley et al., 2011; Hunt et al., 2011; Shimojima
et al., 2006) and a facilitator of DENV infection (Meertens et al.,
2012), had minimal effect on the efficiency of BMDC infection
by the viral pseudotypes (Figure 1E). This was consistent with
the fact that Gas6, the ligand required for Axl activation and
the bridging of Axl to PtdSer on the virus membrane, was not
present in these BMDC experiments.
TAM Receptors Potentiate a Postentry Step
of Enveloped Virus Replication
To determine whether TAM receptors are associated with
increased pseudotyped virus entry into BMDCs, we employed
an established HIV-1 reporter system for assaying cytosolic
delivery that used a viral core protein (Vpr) fused to b-lactamaseCell Hos(BLAM) (Barnard et al., 2004; Cavrois et al., 2004). Entry-medi-
ated delivery of Vpr-BLAM to the cytosol cleaves a cytoplasm-
trapped fluorescent substrate (CCF2) that was loaded into target
cells, abolishing its fluorescence energy transfer and resulting in
a shift in peak emission wavelength from 518 nm (green) to
447 nm (blue) after excitation at 409 nm. These studies were
performed at either 4C (to block virus entry) or 37C (to permit
entry). They revealed identical levels of HIV-1 reporter virus entry
into WT and AM DKO BMDCs at 4 hr postinfection (Figure 2A).
Therefore, we conclude that the increased level of pseudo-
typed virus seen with WT versus TAM-deficient BMDCs (Fig-
ure 1E) was due to TAM receptor regulation of events that are
subsequent to delivery of the viral nucleoprotein core complex
to the cytosol.
Additional support for this conclusion came from experiments
in HEK 293T cells in which we asked whether Axl tyrosine kinase
activity was required for TAM potentiation of either initial entry ort & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevier Inc. 139
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Figure 3. Enveloped Virus Potentiates Ligand-Dependent TAM Receptor Activation
(A) Left, WT BMDCs were incubated with increasing concentrations (0.5–2 nM) of purified human Protein S (Pros1), in either Gla-depleted cell culture medium
alone (medium) or along with enveloped VSVg-pseudotyped HIV-1-derived virus that was produced in Gla-depleted medium (VSVg). Cell lysates were prepared
for immunoblot 5 min after virus and/or Pros1 challenge. Mer was specifically immunoprecipitated from these samples, subjected to SDS-PAGE, and
immunoblotted with a phosphotyrosine-specific antibody (IB: pY). Immunoblot analysis was used to confirm equal amounts of Mer in each sample (IB: Mer), and
the amount of protein in each lysate was assessed by immunoblot for Gapdh (IB: Gapdh). Right, virus potentiation of Mer autophosphorylation in the presence of
1 nM Pros1 for 5 min is seen for the enveloped VSVg-pseudotyped virus, but not with WT MAV-1, a nonenveloped virus.
(B) Left, the same experiments as in (A, left) except that WT BMDCs were incubated with 0.25–1 nM of recombinant mouse Gas6 (Gas6), and the tyrosine
autophosphorylation of Axl was monitored (IB: pY). Right, Virus potentiation of Axl autophosphorylation in the presence of 1 nM Gas6 was seen only with the
enveloped VSVg-pseudotyped virus and not with the nonenveloped MAV-1.
(C)Microtiter wells, precoatedwith purified BSA,Gas6, or Pros1 (10 mg/ml ON for each protein) and incubatedwith equivalent amounts of VSVg-HIV (50 ng/ml p24
concentration) at 37C for 2 hr with or without 5mMEDTA, and the amount of bound virus wasmeasured by ELISA for p24 protein (see Experimental Procedures).
Error bars are SD of three samples. Results are representative of three independent experiments.
See also Figure S2.
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have demonstrated that Axl facilitation of DENV entry does not
require Axl kinase activity, but that potentiation of subsequent
DENV replication required a catalytically competent Axl kinase
(Meertens et al., 2012). We generated stable HEK 293T cell lines
that expressed approximately equivalent levels of either hemag-
glutinin (HA)-tagged WT or kinase-dead mutant Axl (AxlKD, a
D666A mutation in the catalytic domain; Figure 2B). As before
(Figure 1B), ectopic expression of WT Axl in HEK 293T cells
lead to ligand-independent Axl activation (Figure 2B). However,
ectopically expressed AxlKD was catalytically inactive, even in
the presence of added Gas6 (Figure 2B). These two HEK 293T
cell lines were infected with WNV and assayed for virus entry
at 2 and 4 hr postinfection with immunohistochemistry and
flow cytometry with antibodies to the WNV E protein. We found
that WNV entered Axl-expressing and AxlKD-expressing HEK
293T cells equally well (Figure 2C). In parallel experiments, we
also measured WNV replication by titering the virus present in
extracellular supernatants at 4 and 24 hr postinfection. In keep-
ing with the earlier DENV results (Meertens et al., 2012), we found
that WNV titers in AxlKD HEK 293T cells were markedly reduced
at 24 hr postinfection relative to HEK 293T cells expressing WT
Axl (Figure 2D). These results also argue that TAM tyrosine
kinase activity is required for enhancing a postentry step of
WNV replication but has no impact on virus entry. We conclude
that, although TAM receptors can promote virus infection by
providing a docking site on cells and facilitating initial entry, as
described by others, they also operate as signaling proteins140 Cell Host & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevithat render target cells more susceptible to postentry replication
steps and productive infection.
Ligand-Dependent Activation of TAM Receptors during
Enveloped Virus Entry
Given that TAM receptors must be catalytically active in order
to promote viral infection, we considered the possibility that
viruses themselves might function as TAM activators. We
hypothesized that TAM tyrosine kinase activity might be stimu-
lated—directly and immediately—by ligand-coated virus parti-
cles and that this activation might, in turn, inhibit innate immune
responses that would otherwise antagonize infection. To deter-
mine whether endogenous TAM receptors are activated upon
virus challenge, WT BMDCs were challenged with a VSVg-
pseudotyped virus in either the presence or absence of purified
Protein S or Gas6. For these experiments, the culture medium
used during virus production and challenge was depleted of
all Gla domain containing proteins, including Protein S, with so-
dium citrate and barium chloride precipitation (Souri et al.,
2005). The addition of purified Protein S or Gas6 alone led to
a rapid (5 min) dose-dependent activation of Mer or Axl, respec-
tively (Figures 3A and 3B, left panels, lanes 1–4). Autophosphor-
ylation of Axl, for example, was first detectable at 0.5 nM Gas6
(Figure 3B).
The addition of the VSVg-pseudotyped virus along with the
ligands potentiated the stimulatory effects of both Gas6 and
Protein S, shifting their dose response curves to lower protein
concentrations (Figures 3A and 3B, left panels, lanes 5–8).er Inc.
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observed at the same 0.5 nM concentration of Gas6, at which
activation was barely detectable in the absence of virus
(compare lanes 3 and 7 in Figure 3B). Virus-mediated potentia-
tion of Protein S- or Gas6-triggered TAM ligand signaling was
not seenwithmouse adenovirus type 1 (MAV-1), a nonenveloped
virus that does not display PtdSer and, therefore, should not bind
either ligand (Figures 3A and 3B, right panels). Correspondingly,
MAV-1 challenge of WT and AM DKO BMDCs resulted in a com-
parable induction of IFNa4, IFNb, tumor necrosis factor a (TNFa),
and SOCS1/3 messenger RNAs (mRNAs) (data not shown), and
the efficiency of MAV-1 infection in BMDCs was not influenced
by the presence or absence of TAM receptors (Figure S1A
available online).
These results suggest that virus-associated PtdSer is required
for TAM activation. To assess this further, we asked whether
TAM ligands can bind to PtdSer on the virion surface and
whether this binding was required for the viral enhancement of
TAM activation. PtdSer binding by Gla-domain-containing
proteins is Ca+2 dependent (Huang et al., 2003). Consistent
with this dependence, purified Gas6 and Protein S immobilized
onto microtiter wells bound VSVg-pseudotyped virus in a
Ca+2-dependent manner (Figure 3C). In addition, incubation of
VSVg-pseudotyped virus with a limiting concentration (100 nM)
of the PtdSer-binding protein annexin V significantly attenuated
VSVg-HIV potentiation of the Gas6 dose response curve for Axl
activation in BMDCs (Figure S1B). Finally, we generated ‘‘bald’’
HIV-1 virions lacking any viral glycoprotein. As expected, these
bald virions were noninfectious in BMDCs (Figure S2A). How-
ever, they were as competent as VSVg-pseudotyped virions
at potentiating Gas6-induced Axl activation (Figure S2B). Thus,
the ability of the pseudotyped virus to activate TAM receptors
was dependent on the presence of PtdSer but independent of
any specific viral glycoprotein. We hypothesize that Protein S
and Gas6 bound to PtdSer on the enveloped virus surface act
as virion-tethered ‘‘superligands’’ that rapidly activate TAM
receptors upon contact with the target cell surface.
Virus-Mediated TAM Receptor Activation Blunts
the Cellular Antiviral Response
TAM receptor activation in DCs leads to the inhibition of signaling
by host cytokines, including type I IFNs (Rothlin et al., 2007).
Given that the latter are potent antiviral cytokines, we assessed
whether virus-mediated activation of TAM receptors blunts the
cellular antiviral response. BMDCs derived from either WT or
TAM TKO mice (Lu et al., 1999; Lu and Lemke, 2001; Rothlin
et al., 2007) were challenged with the four pseudotyped HIV-1-
derived viruses, and the expression of type I IFN mRNAs was
monitored from 1–24 hr after virus addition. Virus infection of
WT BMDCs resulted in only minimal induction of mRNAs encod-
ing the type I IFNs IFNb and IFNa4 (blue bars in Figures 4A and
4B, respectively).
In marked contrast, the same challenge led to a robust induc-
tion of these mRNAs, ranging from 20- to 80-fold in TAM TKO
BMDCs (red bars Figures 4A and 4B). Virus infection also led
to a significant elevation of TNFa, interferon regulatory factor 5
(IRF-5), and IRF-7 mRNAs in TAM TKO BMDCs, but not in WT
BMDCs (see Figures S3B–S3D). The reciprocal effect was
seen for mRNAs encoding the cytokine signaling inhibitorCell HosSOCS1 (Figure 4C) and, to a lesser extent, SOCS3 (Figure S3A),
which were more upregulated after retrovirus infection in WT
BMDCs than in TAM TKO BMDCs. Altogether, these results indi-
cate that virus-triggered TAM receptor activation in DCs is asso-
ciated with a marked inhibition of type I IFN signaling.
TAM Receptor Antagonism of Type I IFN Signaling
Promotes Virus Replication in DCs
To determine the contribution of TAM-dependent type I IFN inhi-
bition to the efficiency of lentivirus infection, we used neutralizing
antibodies that bind to IFNa and IFNb (see the Experimental Pro-
cedures) to block the action of type I IFNs during virus challenge
of BMDCs. The antibody cocktail had no impact on the level of
infection seen with WT BMDCs (Figure 5A, blue bars), a result
consistent with the minimal type I IFN induced in these cells after
virus challenge (Figures 4A and 4B, blue bars). However, these
antibodies restored the level of infection seen with TAM TKO
BMDCs nearly to that seen with WT BMDCs (Figure 5A, red
bars). Therefore, a primary effect of virus-mediated TAM activa-
tion in DCs appears to be inhibition of the antiviral type I IFN
response.
One implication of these data is that antagonists targeting
TAM receptors, such as small-molecule TAM tyrosine kinase
inhibitors, might confer an antiviral effect through their ability to
block virus-induced TAM-dependent attenuation of type I IFN
signaling. To test this idea, we used BMS-777607, an ATP
mimetic that targets the c-Met, TAM, and Ron tyrosine kinases,
which are closely related in structure (Schroeder et al., 2009).
This orally administered compound has already been used in
human clinical trials for the treatment of advanced or metastatic
solid tumors and is most potent as an inhibitor for Axl (IC50 =
1.1 nM in vitro) among all kinases assayed (Schroeder et al.,
2009). BMS-777607 strongly inhibited the ligand-dependent
activation of both Axl and Mer in cultured cell assays, effectively
blocking Gas6-triggered receptor activation at concentrations
ranging from 30–300 nM (Figure 5B). WT BMDCs treated with
BMS-777607 were much less susceptible to virus infection
than untreated cells (Figure 5C, blue bars). Importantly, the
loss of infectivity seen with TAM TKO BMDCs (Figure 1E) was
not reduced further by the addition of BMS-777607 (Figure 5C),
suggesting that the drug reduces virus infection in WT BMDCs
by blocking the activation of TAM receptors, as opposed to other
RTKs, or through nonspecific cytotoxic effects. (We used a lumi-
nescent cell viability assay [see the Experimental Procedures]
and detected no BMDC cytotoxicity for BMS-777607 from 10–
1,000 nM [Figure S4].) It should be noted that BMS-777607
potently blocks TAM kinase activity without diminishing either
Axl or Mer protein expression (Figure 5B; Axl and Mer immuno-
blots). This suggests that virus attachment to an inactive TAM
receptor on a target cell is not sufficient to promote infection in
this system.
TAM Receptor Antagonism Reduces WNV Infection
in a Type I IFN-Dependent Manner
Given that gain-of-function studies (Meertens et al., 2012) have
shown that TAM facilitation of virus infection extends to flavivi-
ruses (DENV and WNV), we asked whether our loss-of-function
results with HIV-1-derived pseudoviruses also extend to WNV,
aWT virus that (unlike DENV) can infect mouse DCs.We infectedt & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevier Inc. 141
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Figure 4. Enveloped Virus Infection Abrogates the Cellular Antiviral Response in a TAM-Dependent Manner
(A–C) WT BMDCs (blue bars) or TAM TKO BMDCs (red bars) were challenged with the pseudotyped viruses of Figure 1B. Expression levels of IFNa4 (A), IFNb (B),
and SOCS1 (C) mRNAs were measured by qRT-PCR at the indicated time points after virus addition. The levels of the indicated mRNAs were normalized to
control b-actin mRNA. *p < 0.05; **p < 0.01; ***p < 0.001. Results comparable to those for IFNa4 and IFNbmRNAs were seen for measurements of TNFa, IRF-5,
and IRF-7 mRNAs (see Figure S3). Error bars are SEM of samples from three independent experiments.
See also Figure S3.
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TAM Signaling Disables Antiviral Defenseseither WT or AM DKO BMDCs with WNV and measured virus
levels 24 hr later. We observed a 10-fold reduction in infectivity
in the AM DKO BMDCs relative to WT BMDCs (Figure 5D). Simi-
larly, treatment with BMS-777607 reduced WNV infection of WT
BMDCs by approximately 10-fold, but this treatment had no
additional effect on the reduced WNV infectivity seen for AM
DKO BMDCs (Figure 5D). This also suggests that the antiviral142 Cell Host & Microbe 14, 136–147, August 14, 2013 ª2013 Elseviactivity of BMS-777607 is specific to its action as an inhibitor
of TAM receptors as opposed to other RTKs.
To examine the contribution of type I IFN signaling to the effect
of TAM inhibition on WNV replication, we generated BMDCs
from Ifnar1/ mice, which lack the R1 chain of the type I IFN
receptor and are signaling incompetent (Mu¨ller et al., 1994).
WNV is very sensitive to type I IFNs and replicates to mucher Inc.
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Figure 5. The Primary Effect of TAM Receptor-Ligand Interactions on Virus Infection in BMDCs Is to Inhibit the Cellular Antiviral Response
(A) WT BMDCs and TAM TKO BMDCs were incubated with VSVg-pseudotyped virus in either the absence () or presence (+) of 100 mg each of neutralizing anti-
mouse IFNa and IFNb antibodies, and the levels of HIV-1 DNA were measured at 24 hr postinfection. Results were normalized to the level of viral DNA seen with
WT BMDCs incubated with no antibody (100%, dashed blue line). ***p < 0.001. Error bars are SEM of samples from three independent experiments.
(B) WT BMDCs were preincubated for 30 min with or without BMS-777607 and stimulated with Gas6 for 10 min. Receptor activation was monitored with the
immunoprecipitation and immunoblotting protocol shown in Figure 3; this protocol employed a phosphotyrosine-specific antibody (pY). Immunoblot was used to
confirm equal amounts of Mer and Axl in each sample.
(C) WT BMDCs and TAM TKOBMDCswere incubated with EbGP-pseudotyped virus in the absence () or presence (+) of 300 nMBMS-777607, and the levels of
HIV-1 viral DNAweremeasured at 24 hr postinfection. Results were normalized to those seen withWT BMDCs (100%, dashed blue line). **p < 0.01. Error bars are
SEM of samples from three independent experiments.
(D) WT BMDCs (blue bars), AM DKO BMDCs (red bars), and IFNAR KO BMDCs (green bars) were incubated with WNV in the absence () or presence (+) of 1 mM
BMS-777607, and the levels of infectious virus (PFU per ml) weremeasured at 24 hr postinfection. ***p < 0.001. Error bars are SEM of three independent samples.
Results are representative of three independent experiments. BMS-777607 effects are not due to cytotoxicity (see Figure S4).
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(Samuel and Diamond, 2005, 2006). Consistent with this, WNV
titers were 100-fold higher in Ifnar1/ BMDCs than WT cells
(Figure 5D). However, in contrast to WT BMDCs, the BMS-
777607 TAM inhibitor had no effect on WNV replication in these
Ifnar1/ cells (Figure 5D). Combinedwith our results showing no
effect of TAM receptors on initial virus entry steps (Figures
2A–2C) and the type I IFN dependence of the inhibitor on pseu-
dovirus infection (Figure 5A), these findings suggest that BMS-
777607 inhibits pseudovirus and WNV infection of DCs by
blocking the ability of virus-activated TAM receptors to downre-
gulate the cellular type I IFN response. The fact that there was no
impairment of virus infection by BMS-777607 in Ifnar1/
BMDCs (Figure 5D) argues against the possibility that this inhib-
itor acts through a nonspecific cytotoxic mechanism.Cell HosDISCUSSION
We describe a mechanism of enveloped virus evasion of host
innate immune responses that is based on TAM receptor acti-
vation through apoptotic mimicry. We propose that PtdSer—
exposed on the surface of an enveloped virus—binds, concen-
trates, and reduces the free diffusion of extracellular Protein S
and Gas6, which, therefore, appear to act as superligands for
activating cell surface TAM receptors during initial contact with
the target cell surface. In DCs, and perhaps other cell types,
TAM receptor activation leads to the downregulation of host
TLR and type I IFN signaling pathways (Figure 6). Indeed, this
appears to be the main mechanism behind TAM-receptor-stim-
ulated infection of BMDCs, given that type I-IFN-neutralizing
antibodies reversed the pseudovirus infection defect that wast & Microbe 14, 136–147, August 14, 2013 ª2013 Elsevier Inc. 143
Figure 6. Virus-Ligand Activation TAM of TAM Receptors Inhibits
the Antiviral Immune Response
A model showing that the major effect of TAM receptor-ligand interactions on
enveloped virus infection of dendritic cells is at the level of inhibiting the cellular
innate immune response, including TAM inhibition of type I IFN signaling.
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TAM Signaling Disables Antiviral Defensesseen with TAM-deficient BMDCs (Figure 5A) and a pharmaco-
logical TAM inhibitor blocked WNV infection of WT, but not
Ifnar1/, DCs (Figure 5D).
These results do not rule out the possibility that TAM receptor-
ligand interactions, including interactions that rely on the
activation of TAM kinase activity, also play an important role in
promoting virus uptake and initial entry into other cell types
(Brindley et al., 2011; Meertens et al., 2012; Morizono et al.,
2011; Shimojima et al., 2007; Shimojima et al., 2012; Shimojima
et al., 2006). However, it should be noted that the Axl cyto-
plasmic domain and its tyrosine kinase activity are dispensable
for the initial uptake of DENV particles into HEK 293T cells that
ectopically express this receptor but are required for Axl poten-
tiation of DENV proliferation, which occurs over the next 48 hr
(Meertens et al., 2012), in these cells. This is the only published
study in which the requirement for TAM kinase activity has
been examined in the context of initial virus entry versus later
stages of infection, although other studies have similarly shown
that an active TAM tyrosine kinase is required for TAM potentia-
tion of infectivity measured 48 hr after virus challenge (Shimojima
et al., 2007; Shimojima et al., 2012). This is the case even though
kinase-dead mutants of both Axl and Tyro3 have been found to
bind ligand-opsonized virus particles as effectively as their WT
counterparts (Shimojima et al., 2007; Shimojima et al., 2012).
Our gain-of-function studies with WNV (Figures 2B and 2C)
demonstrate that Axl tyrosine kinase activity is dispensable for
WNV entry into HEK 293T cells (which express endogenous
Tyro3 andMer) but is required for Axl potentiation of subsequent
events in WNV infection.
Our studies were conducted with pseudotyped HIV-1-based
viruses and WNV as model enveloped viruses. Previously,
PtdSer on pseudotyped lentiviruses and DENV was shown to
bind TAM ligands (Meertens et al., 2012; Morizono et al.,
2011). The presence of exposed PtdSer is also a feature of
WT retroviruses as well as arenaviruses, poxviruses, filoviruses,144 Cell Host & Microbe 14, 136–147, August 14, 2013 ª2013 Elseviand alphaviruses (Callahan et al., 2003; Jemielity et al., 2013;
Mercer and Helenius, 2008). Given that PtdSer exposure seems
to be relatively common, it is possible that many different
enveloped viruses exploit TAM receptor-ligand interaction as a
mechanism for counteracting the antiviral response of TAM-
positive cells.
Our findings suggest a potential antiviral strategy based upon
inhibiting the virus- and ligand-dependent activation of TAM-
receptor-associated signaling pathways (Figures 5C, 5D,
and 6). This strategy is illustrated with BMS-777607, a small-
molecule kinase inhibitor that led to a marked reduction in
virus infectivity for both HIV-1-derived lentivirus and WNV. This
compound not only inhibits the activation of TAM receptors
but also blocks the activities of other closely related tyrosine
kinase receptors, including c-Met and Ron (Schroeder et al.,
2009). However, the fact that BMS-777607 reduced virus
infection in TAM-receptor-expressing WT, but not TAM KO,
BMDCs suggests that its antiviral function is mediated specif-
ically through TAM receptor inhibition. Although an antiviral
approach employing TAM receptor antagonists may not be
suitable for the long-term treatment of virus infections because
of the risk of undesirable side effects, such as autoimmunity
(Rothlin et al., 2007; Rothlin and Lemke, 2010), we anticipate
that shorter-term treatments of acute or chronic virus infec-
tions might be useful for promoting the clearance of enveloped
viruses.
EXPERIMENTAL PROCEDURES
HEK 293T Stable Cell Lines and Mouse BMDC Cultures
Complementary DNAs (cDNAs) for mouse Tyro3 or Axl were subcloned into a
pcDNA6 expression vector (Invitrogen) containing a blasticidin resistance
gene. The construct was transfected into HEK 293T cells, and a stable cell
line was generated by growing cells in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS (SAFC Biosciences), 100 U/ml penicillin
and 100 mg/ml streptomycin (PenStrep), and 10 mg/ml blasticidin. AmouseMer
cDNA was subcloned into a pIRES puro3 vector (Clontech) containing a puro-
mycin resistance gene and transfected into HEK 293T cells, and a stable cell
line was generated by growing cells in medium supplemented with 2.5 mg/ml
puromycin.
Bone marrow cells were isolated from tibias and femurs of 6- to 8-week-old
mice according protocols approved by the International Animal Care and Use
Committee (11-00051), as described previously (Harding et al., 2010), and
were grown for 7 days in RPMI containing 20 ng/ml mouse GM-CSF (Akron
Biotech), 5% FBS, and antibiotic-antimycotic cocktail (Invitrogen) in order to
generate BMDCs. Before stimulation with purified Gas6 or Protein S, cells
were starved overnight (ON) in serum-free RPMI medium.
Virus Production and Infection
Pseudotyped viruses were produced as described previously (Bhattacharyya
et al., 2011). Viruses were treated with 40 U/ml DNase I (Roche) for 1 hr before
being added to cells. HEK 293T cells and HEK 293T cells stably expressing
TAM receptors were plated at 105 cells per well of a 12-well plate and chal-
lenged with 500 ml of each virus stock. DNA was harvested from cells with
quantitative PCR (qPCR) lysis buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA,
0.2 mM CaCl2, 0.001% Triton X-100, 0.001% SDS, and 1 mg/ml proteinase
K) at 24 hr postinfection and subjected to qPCR with TaqMan Fast PCR
(Applied Biosystems) with primers specific for HIV-1 reverse transcribed
HIV-1 DNA products or for the cellular porphobilinogen deaminase (PBGD)
gene, as described previously (Ko¨nig et al., 2008) (Table S1).
HIV-1 DNA levels from TAM-expressing HEK 293T cells were normalized to
PBGD before they were compared to those seen in untransfected HEK 293T
cells. BMDCs (105) were spinoculated with 500 ml of each virus at 1,200 3 g
for 1 hr followed by incubation at 37C. HIV-1 DNA products were measureder Inc.
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normalization to WT BMDCs for each pseudotype. Oligonucleotide primers
and TaqMan probes used for qPCR are listed in Table S1. For measuring
HIV-1 DNA products, a standard curve was generated with six 10-fold serial
dilutions of HIV-1 plasmid DNA. For b-actin, a standard curve was generated
with six 10-fold serial dilutions of uninfected BMDCs or HEK 293T cells.
WNV (strain New York 2000) was produced in C6/36 Aedes albopictus cells
as described previously (Diamond et al., 2003) and was used to infect WT and
AMDKOBMDCs at amultiplicity of infection (moi) of 0.01.WNV titers in culture
medium were measured at 24 hr postinfection by plaque assay on BHK21-15
cells as described previously (Beasley et al., 2002; Diamond et al., 2003). For
adenovirus infection, 105 BMDCs were infected with MAV-1 at an moi of 1.
Cells were lysed 24 hr postinfection, and the expression of adenovirus E1A
was assayed by qRT-PCR and normalized to endogenous cyclophilin A.
BMDCs were pretreated with 0 or 100 mg of neutralizing anti-mouse IFNa
and IFNb antibodies (PBL, IFNa and IFNb) for 3 hr and then spinoculated
with VSVg-pseudotyped virus at 1200 3 g for 1 hr followed by incubation at
37C with or without antibody. Reverse transcribed HIV-1 DNA products
were measured 24 hr postinfection. For BMS-777607 studies, WT or TAM
TKO BMDCs were incubated with EbGP-pseudotyped virus ± 300 nM
BMS-777607, and the levels of HIV-1 DNA were measured at 24 hr postin-
fection. The same protocol was followed for WNV experiments, except that
BMS-777607 was used at 1 mM, and mutant BMDCs were prepared from
AM DKOs.
Immunoprecipitations and Immunoblotting
HEK 293T cells were grown to 80% confluency in DMEM with 10% FBS and
PenStrep. Cells were washed in ice cold PBS and lysed in buffer containing
50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol,
and 1% Triton X-100 supplemented with protease and phosphatase inhibitor
cocktails (Roche). BMDCs were incubated with serum-free medium ON and
then for 5 min with increasing amounts of either human Protein S (Haemato-
logic Technologies) or mGas6 with or without a VSVg-pseudotyped virus or
MAV-1. Cells were washed with cold PBS and lysed on ice in a buffer contain-
ing 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton X-100,
0.27 M sucrose, 0.1% b-mercaptoethanol, and protease and phosphatase
inhibitors.
For western blots, equal amounts of protein (5 mg) in lithium dodecyl sul-
phate (LDS) sample buffer (Invitrogen) were subjected to electrophoresis on
a polyacrylamide gel and transferred to polyvinylidene fluoride (PVDF) mem-
branes. For immunoprecipitations, cell lysates were incubated ON at 4C
with antibodies against Tyro3 (goat polyclonal, C-20, Santa Cruz Biotech-
nology), Axl (goat polyclonal, M-20, Santa Cruz), and Mer (Prasad et al.,
2006), respectively. Protein G or A Sepharose was added for 2 hr, and immu-
noprecipitates (IPs) were washed twice with 1 ml of lysis buffer containing
0.5 M NaCl and once with 1 ml of 50 mM Tris-HCl (pH 7.5). IPs were eluted
in LDS buffer, separated on polyacrylamide gels, and transferred to PVDF
membranes. Membranes were blocked in TBST (50 mM Tris-HCl [pH 7.5],
0.15 M NaCl, and 0.25% [v/v] Tween-20) containing 5% (w/v) BSA and immu-
noblotted ON at 4C with antibodies diluted 1,000-fold in blocking buffer.
Immunoblotting antibodies were anti-Tyro3 and anti-Axl (described above),
anti-Mer (goat polyclonal, AF591, R&D Systems), anti-GAPDH (mouse
monoclonal, clone 6C5, Millipore); and anti-pTyr (pY, mouse monoclonal,
clone 4G10, Millipore). Blots were washed in TBST and incubated for 1 hr at
room temperature with secondary horseradish-peroxidase-conjugated anti-
bodies (GE Healthcare) diluted 5,000-fold in 5% (w/v) skim milk in TBST. After
repeating the washes, signal was detected with enhanced chemilumines-
cence reagent.
Protein S and Gas6 Binding to Virus Particles
Nunc MaxiSorp plates were coated ON with 10 mg/ml of hProS or mGas6.
Wells were washed five times with a buffer containing 10 mM HEPES
(pH 7.4), 150 mM NaCl, 2.5 mM CaCl2, and 0.1% v/v Tween-20, blocked
with 10% w/v BSA for 2 hr at room temperature, and washed as above. Virus
was diluted in DMEM with 5% BSA to p24 concentration 50 ng/ml, and 100 ml
was added to wells with or without 5 mM EDTA and incubated at 37C for 2 hr.
Wells were washed as above, and bound virus was lysed and measured with a
p24 ELISA Kit (ZeptoMetrix).Cell HosVpr-BLAM BMDC Infection and Assay
VSVg-HIV Vpr-BLAM virus stocks were prepared by transfection of HEK 293T
cells (Barnard et al., 2004; Cavrois et al., 2004). Virus entry was assayed by
infection with virions containing Vpr-BLAM and by loading target cells with
CCF2. Upon entry, CCF2-AM was cleaved by esterases, and, in the absence
of BLAM, excitation at 409 nm (405 nm filter) results in fluorescence resonance
energy transfer (FRET) of the intact CCF2 and peak emission at 518 nm
(535 nm filter). In the presence of BLAM, cleavage of CCF2 disrupts FRET,
and excitation at 409 nm produces a blue fluorescence (465 nm filter). WT
and AM DKO BMDCs were starved ON in serum-free media. Next, 5 3 105
cells were spinoculated at 4C with 0.25 ml of virus stock and incubated in
the presence of virus at 37C for 4 hr. Control cells were kept for 4 hr at 4C
in order to prevent virus entry. Virus was washed away with Hank’s balanced
salt solution (HBSS); cells were resuspended in HBSS and loaded with CCF2
dye for 3 hr with the LiveBLAzer FRET CCF2 Loading Kit (Invitrogen). Fluores-
cence was measured using 405 nm excitation and 465 nm and 535 nm emis-
sion filters. After background subtraction, a 465:535 ratio was calculated.
Response ratio was calculated by dividing 465:535 ratios of experimental
samples by the same ratio of the no-virus control.
Quantitative RT-PCR
BMDCswere infected by spinoculationwith each pseudotyped virus at 1,200 g
for 1 hr followed by incubation at 37C for the indicated time points up to 24 hr.
RNA was isolated from the cells with the RNeasy Mini Kit (Qiagen) and cDNA
was prepared with the QuantiTect Reverse Transcription Kit (Qiagen). qPCR
reactions were performed to measure mRNA expression levels with the oligo-
nucleotide primers listed in Table S1 with Power SYBRGreen PCR Master Mix
(Applied Biosystems). A dissociation curve analysis was performed for each
reaction with the SDS (Applied Biosystems). A standard curve was generated
with six 10-fold dilutions of samples from uninfected BMDCs.
Adenovirus Infection
PurifiedMAV-1 was a generous gift from C. Powers and C. O’ Shea (Salk Insti-
tute). MAV-1 was grown on mouse 3T6 cells, concentrated from supernatant
with PEG precipitation, and purified on a CsCl gradient. Purified virus was
dialyzed in 10% glycerol, 10 mM Tris (pH7.5), 150 mM NaCl, and 1 mM
MgCl2 and titered by plaque assay on 3T6 cells. 10
5 BMDCs were infected
withMAV-1 at anmoi of 1. Cells were lysed at 1, 2, 4, 6, and 24 hr postinfection,
and mRNA was isolated with a RNeasy Kit with DNase digestion.
Purification of Recombinant Mouse Gas6
A mammalian expression vector was engineered to encode full-length mouse
Gas6 followed by a C-terminal TEV-cleavable His6 tag. This vector was trans-
fected into HEK 293T cells, and cells stably expressing the construct were
selected in DMEM supplemented with 10% FBS, PenStrep, 0.25 mg/ml
G418, and 100 mg/ml hygromycin B. For expression studies, cells were grown
in serum-free medium containing 10 mM vitamin K2, and conditioned medium
was collected after 72 hr. Gas6 was isolated with affinity chromatography with
Ni-NTA beads followed by purification on a HiTrap Q FF ion exchange column
(GE Healthcare). The protein was eluted in 20 mM Tris (pH 8) with a sodium
chloride gradient up to 1 M.
Cytotoxicity Assay
BMS-777607 cytotoxicity in WT BMDCs was measured with a CellTiter-Glo
Luminescent Cell Viability Assay (Promega).
SUPPLEMENTAL INFORMATION
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